Insignificant prostate cancer in radical prostatectomy specimen: Time trends and preoperative prediction

European Urology

Volumn 43, Issue 5, 2003, Pages 455-460

  Augustin, Herbert ^a,b   Hammerer, Peter G ^a,c   Graefen, Markus ^a   Erbersdobler, Andreas ^a   Blonski, Jakob ^a   Palisaar, Jüri ^a   Daghofer, Fedor ^b   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GRAZ   (Austria)

^c Department of Urology   (Germany)

Author keywords

Insignificant cancer; Prostate cancer; PSA density; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROSTATECTOMY; STATISTICAL MODEL; TUMOR DIFFERENTIATION; TUMOR LOCALIZATION;

EID: 0038304585     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(03)00139-8     Document Type: Article

References (21)

1. Franks LM. Latent carcinoma of the prostate. J Pathol 1954;68:603-16.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23-47.
3. Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 1998;159:1431-6.
4. Walsh PC. Surgery and the reduction of mortality from prostate cancer. N Engl J Med 2002;347:839-41.
5. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Cancer 1993;71(Suppl):933-8.
6. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-74.
7. Mettlin CJ, Murphy GP. Why is the prostate cancer rate declining in the United States? Cancer 1998;82:249-51.
8. Sobin LH, Wittekind C. Prostate. In: Sobin LH, Wittekind C, editors. UICC TNM Classification of Malignant Tumors. 5th ed. New York: Wiley-Liss; 1997. p. 170-3.
9. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
10. Henke RP, Krueger E, Ayhan N, Huebner D, Hammerer H, Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol 1994;152:1297-301.
11. Gleason DJ, Mellinger GT. Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
12. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996;156:1059-63.
13. Etzioni R, Penson DF, Legler JM, Di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 2002;94:981-90.
14. Stamey TA, Donaldson AN, Yemoto CE, McNeal JE, Sozen S, Gill H. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998;160:2412-7.
15. Soh S, Kattan MW, Berkman S, Wheeler TM, Scardino PT. Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol 1997;157:2212-8.
16. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001;166:104-9.
17. Hautmann SH, Conrad S, Henke RP, Erbersdobler A, Simon J, Straub M, et al. Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology. J Urol 2000;163:1734-8.
18. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol 1997;157:2206-9.
19. Carter BH, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002;167:1231-4.
20. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-94.
21. Lewis JS, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screeing population. Am J Clin Pathol 2002;118:442-50.